[SaneVax: Scientists and medical professionals the world over are beginning to question and investigate current vaccination practices and paradigms. The following is an excerpt from a letter to the editor of The Journal of Internal Medicine, questioning the findings of a ‘study’ funded by the manufacturer of Gardasil. Medical consumers the world over need to begin asking the same questions of their medical providers.]
No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil?L. Tomljenovic1, C. A. Shaw1,2,3 Article first published online: 24 MAY 2012 DOI: 10.1111/j.1365-2796.2012.02551.x © 2012 The Association for the Publication of the Journal of Internal Medicine
Recently, the Journal of Internal Medicine published a study by Chao et al.  on autoimmune conditions following the routine use of Gardasil, which failed to identify any significant autoimmune safety concerns. This study was conducted in collaboration between two managed care organizations, Kaiser Permanente Southern California (KPSC) and Kaiser Permanente Northern California (KPNC), as a postlicensure commitment to the FDA, the European Medicines Agency (EMA) and other regulatory authorities to help evaluate the autoimmune safety of the vaccine. In particular, Chao et al.  noted that ‘well-designed postlicensure safety studies for newly approved vaccines facilitate proper evaluation of their autoimmune safety’ [emphasis added]. We certainly do agree with the authors that such studies are needed for determining whether or not new vaccines have adequate safety profiles. The study population for the autoimmune surveillance by the Kaiser’s research team thus included 189,629 women of diverse ethnical and socio-economic background, 99% of whom were in the recommended age range for HPV vaccination (9–26 years) . Nonetheless, two potential biases might have influenced the outcome of the safety analysis conducted by the authors.